OR WAIT null SECS
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of James Hassard as chief commercial officer. Mr. Hassard is a commercial leader with more than three decades of experience leading sales and marketing operations for both global and domestic biotechnology companies.
Scott Struthers, Ph.D., founder and chief executive officer of Crinetics, stated, “In addition to his deep biopharmaceutical experience, Jim’s background as a pharmacologist gives him valuable scientific insight that informs his commercial strategy. These are critical skills that we will leverage across our pipeline of nonpeptide drug candidates..."
Prior to joining Crinetics, Jim Hassard was chief commercial officer at Arrowhead Pharmaceuticals, Inc., where he began building the company’s commercial capabilities and launch strategy for three rare disease programs.
“It’s an exciting time to join Crinetics,” added Mr. Hassard. “The company’s near-term need is to ensure commercial readiness in multiple geographies for paltusotine, which holds promise as a treatment for patients with acromegaly. Beyond that, I look forward to working with the team to develop strategic approaches to the company’s rich pipeline of small molecule drug candidates and am honored to be part of Crinetics’ mission to help patients with these rare endocrine disorders.”